MedTrace Logo

Electronic Alerting Tool to Help Prevent Acute Kidney Injury

NCT03047382 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30298

Last updated 2017-02-09

No results posted yet for this study

Summary

Around a third of patients who develop acute kidney injury (AKI) do so after a hospital admission (hospital-acquired - HA-AKI).

The primary aim of the study is to prospectively test whether introducing a complex intervention (a 'care package' - comprising a clinical prediction rule incorporating an electronic alert which generates a checklist for patient management to relevant health professionals) can identify patients on admission to hospital who are at risk of developing HA-AKI, highlight the need for closer monitoring and allow putative preventative measures to be put in place.

The investigators will introduce the care package in one acute hospital and evaluate its effectiveness in reducing HA-AKI and its associated morbidity, over ten months, compared to a sister hospital within the same Trust (which will act as a control site). The investigators will extend evaluation for a further ten months to assess sustainability on the first site and introduce the package at the control hospital to assess generalisability. The primary aim is reducing HA-AKI, but secondary aims will include improved outcomes associated with HA-AKI, management of patients already with AKI on admission to hospital (whose care may also benefit from the checklist) and a cost-effectiveness analysis.

Conditions

Interventions

OTHER

AKI Care Bundle

Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.

Sponsors & Collaborators

  • University of Southampton

    collaborator OTHER

  • Western Sussex Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Richard Venn, MBBS · Western Sussex Hospitals NHS FT

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-04-30
Completion
2016-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03047382 on ClinicalTrials.gov